This post has been archived and contains information that may be out of date.
The Food and Drug Administration (FDA) has issued draft guidance on insanitary compounding, attached below. The goal of the FDA’s guidance is help drug compounding facilities identify insanitary conditions, which can result in serious harm to patients. Comments on the draft guidance are due on October, 3 2016.
